FinscoFinsco

Halozyme Therapeutics (US.HALO)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.HALO · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion97.9%→
ROE68.3%↑
Cash Conversion120.0%↓
D/E Ratio9.76↓
Gross Margin79.0%→
US.HALO (Halozyme Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    97.9%    →
ROE               68.3%    ↑
Cash Conversion  120.0%    ↓
D/E Ratio          9.76    ↓
Gross Margin      79.0%    →
Key Metrics
US.HALO (Halozyme Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 97.9% →
ROE 68.3% ↑
Cash Conversion 120.0% ↓
D/E Ratio 9.76 ↓
Gross Margin 79.0% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies